To Buy or Not to Buy

At Forbes's Science Business blog Matthew Herper wonders whether Amgen should acquire Human Genome Sciences. Biotech analyst Geoffrey Porges says it should, and that the price tag could be as high as $6.5 billion. Porges points out that Benlysta, Human Genome's lupus drug, is "one of the hotter biotech products" and that Amgen has more to offer Human Genome than GlaxoSmithKline, which has the rights to co-market Benlysta, does.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.

Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.

The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.

In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.